News digest – Testosterone, artificial intelligence, genetic tests, the HPV vaccine and… a cuppa? – Cancer Research UK

  • Our top story: women who have had the human papillomavirus (HPV) vaccine could need just 3 cervical screens in their lifetime to get the same benefits as the current 12 offered to women in the UK. The BBC, Times, Guardian and many others covered this important research, and our blog post explores it in more depth.
  • New NHS data also showed a worrying trend that fewer women are attending cervical screening than in previous years. Our news report has the details.
  • This week the annual National Cancer Research Institute (NCRI) Cancer Conference was held in Liverpool, where a number of exciting science presentations made headlines. First up was widely-reported research from the University of Oxford, which found that unusually low levels of testosterone in the blood could be linked with a reduced risk of prostate cancer. Our press release has more.
  • Next up from NCRI: Cambridge researchers have developed a new genetic test that could help predict if someone will go on to develop oesophageal cancer up to 8 years earlier than when symptoms start to show. But, as our press release explains, this work only looked at people who have Barrett’s oesophagus, and are at a higher risk of developing the disease. The Times and Telegraph covered this story.
  • More on the subject of genetic tests with research suggesting new criteria are needed to decide which cancer patients should have tests for faulty BRCA genes, which increase the risk of breast and ovarian cancers. The Telegraph covered this one.
  • Another genetic test developed by scientists could spare some breast cancer patients from chemotherapy, reports the Mail Online. By determining how aggressive the disease is, the test could indicate whether the tumour is likely to respond to chemotherapy or not.
  • Findings from an early clinical trial presented at NCRI showed an ovarian cancer drug can make its way through the protective blood brain barrier of patients and reach certain brain tumours. As our press release explains, this barrier prevents many drugs from reaching the brain, so the results are an important first step in developing the targeted drug as a potential treatment for glioblastoma. The BBC has more on the story.
  • Using artificial intelligence to crunch vast amounts of data could help make radiotherapy for prostate cancer more personal, according to more research showcased at NCRI. Picked up by The Telegraph, Times and others, the technique could help…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *